Farallon Capital Management’s Beam Therapeutics BEAM Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$242M	Buy	10,134,696 +71,585	+0.7%	+$1.99M	1.57%	26
2025 Q4	$279M	Hold	10,063,111	–	–	1.53%	29
2025 Q3	$244M	Buy	10,063,111 +50,000	+0.5%	+$995K	1.38%	33
2025 Q2	$170M	Buy	10,013,111 +85,000	+0.9%	+$1.48M	0.78%	40
2025 Q1	$194M	Buy	9,928,111 +1,688,988	+20%	+$44.2M	1.05%	38
2024 Q4	$204M	Buy	8,239,123 +31,000	+0.4%	+$791K	1.08%	39
2024 Q3	$201M	Buy	8,208,123 +295,000	+4%	+$7.62M	1.1%	39
2024 Q2	$185M	Buy	7,913,123 +3,401,370	+75%	+$83.5M	1.09%	39
2024 Q1	$149M	Buy	4,511,753 +406,000	+10%	+$12.6M	0.88%	39
2023 Q4	$112M	Sell	4,105,753 -376,086	-8%	-$9.34M	0.7%	44
2023 Q3	$108M	Buy	4,481,839 +1,040,317	+30%	+$27.9M	0.61%	39
2023 Q2	$110M	Buy	3,441,522 +9,601	+0.3%	+$312K	0.66%	47
2023 Q1	$105M	Buy	3,431,921 +32,000	+0.9%	+$1.26M	0.64%	48
2022 Q4	$133M	Sell	3,399,921 -231,350	-6%	-$10.4M	0.86%	41
2022 Q3	$173M	Buy	3,631,271 +159,000	+5%	+$9.07M	1.06%	39
2022 Q2	$134M	Buy	3,472,271 +877,884	+34%	+$34.9M	0.79%	44
2022 Q1	$149M	Buy	2,594,387 +329,342	+15%	+$21.6M	0.82%	38
2021 Q4	$181M	Buy	2,265,045 +547,455	+32%	+$46.9M	1.02%	34
2021 Q3	$149M	Buy	1,717,590 +217,590	+15%	+$21.9M	0.8%	42
2021 Q2	$193M	Buy	1,500,000 +907,519	+153%	+$72.3M	0.93%	38
2021 Q1	$47.4M	Buy	+592,481	New	+$56.4M	0.25%	74
2020 Q2	–	Sell	-170,164	Closed	-$3.06M	–	121
2020 Q1	$3.06M	Buy	+170,164	New	+$3.7M	0.03%	91